FY25 AGM Presentation and Update
Filed with ASX · · 12 pages · English
World leading medical technology (ASX:UCM) with global footprint – Sydney, Singapore, Beijing, Budapest, London Delaware • Cardiovascular and pulmonary devices • Expanding product portfolio • Digital technology • Wireless connectivity • Flagship science and technology in prestige cardiovascular and pulmonary sector. • Multiple products with global regulatory • Addressing diseases responsible for >
In the deck
Story so far
Earlier from Uscom
- Quarterly Activities/Appendix 4C Cash Flow Report
- Sale of Uscom Business
- Suspension from Quotation
- Preliminary Final Report
- FY24 AGM Presentation and Update
Later from Uscom
- Long Term Suspended Entities
- Quarterly Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
- Suspension from Official Quotation - Annual Listing Fees
Follow Uscom into a list and get an email when it puts out news.
Follow Uscom